Close Menu

Cenix BioScience

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cytoo will coordinate a project announced on Monday that aims to combine high-throughput applications of RNAi with Cytoo's new cell normalization technology.

Cenix BioScience announced this week that it has signed a research agreement with Sygnis Bioscience.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Becton Dickinson announced the latest round of winners of its BD Biosciences Research Grant Program. Winners will receive $10,000 worth of research reagents for their projects.

The deal represents an expansion of an ongoing partnership between Cenix and Janssen focused on improving in vivo siRNA-based target validation methodologies in the central nervous system.

Cenix Joins EU siRNA Consortium

Premium

Cenix jumped on board after one-time member Novosom dropped out following the sale of its liposome-based delivery technology to Marina Biotech last year.

The new unit is part of "a major growth and diversification initiative ongoing since 2008 to broaden the company's range of activities beyond [its core] cell-based RNAi services," Dresden, Germany-based Cenix said.

The company has added respiratory and inflammation to an RNAi screening program that began with oncology.

The company, which until recently has focused almost exclusively "on cell-based work," expects that the delivery technology will facilitate its in vivo work and enable RNAi-based therapeutics.

The company will use RNAi technologies for cell-based screens for cancer drugs.

Strands: Feb 5, 2009

Premium

Isis Pharmaceuticals, Champions Biotechnology, Gradalis, Mirna Therapeutics, University of California, San Francisco, Cenix BioScience, Boehringer Ingelheim, RXi Pharmaceuticals, YA Global

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.